Drug intelligence / Profile preview

PHV04

Development stage: Preclinical
Lead developer: Public Health Vaccines
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

PHV04 is a live attenuated viral vector vaccine candidate developed by Public Health Vaccines for the prevention of Bundibugyo virus disease (BDBV). It utilizes the recombinant vesicular stomatitis virus (rVSV) platform, where the native VSV glycoprotein (G) is replaced with the glycoprotein (GP) of the Bundibugyo virus. This platform is designed to induce a protective immune response by presenting the viral glycoprotein to the host immune system. PHV04 is currently in the preclinical stage of development.

Other names: rVSV-BDBV-GPrVSV-Bundibugyo vaccine

Targets

Bundibugyo ebolavirus surface glycoprotein

Beyond the preview

Go deeper on PHV04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHV04.

Explore the full profile